BioNTech SE (BSP:B1NT34) Total Long-Term Assets: R$33,508 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:B1NT34 BioNTech SE BSP:B1NT34
53 GF Score
Price R$28.53
GF Value R$26.90
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is BioNTech SE Total Long-Term Assets?

BioNTech SE BSP:B1NT34 -2.06% 53 Total Long-Term Assets is R$33,508 Mil as of Mar. 2026. GuruFocus rates BSP:B1NT34 with a GF Score™ of 53/100 and a GF Value™ of R$26.90 (Fairly Valued). The stock has 4 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. BioNTech SE's Total Long-Term Assets for the quarter that ended in Mar. 2026 was R$33,508 Mil.

BioNTech SE Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for BioNTech SE's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioNTech SE Total Long-Term Assets Chart

BioNTech SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,846.60 7,540.82 18,589.32 23,804.76 37,321.08

BioNTech SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34,591.55 36,514.65 34,685.77 37,321.08 33,507.53
BSP:B1NT34
53GF Score
BioNTech SE BSP:B1NT34
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioNTech SE Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of R$33,508 Mil mean?
BioNTech SE (BSP:B1NT34) has a Total Long-Term Assets of R$33,508 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on BioNTech SE and its competitors.
Is BioNTech SE's Total Long-Term Assets too high?
BioNTech SE's current Total Long-Term Assets is R$33,508 Mil. Overall, BioNTech SE has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioNTech SE's Total Long-Term Assets compare to INCY and INSM?
BioNTech SE's Total Long-Term Assets of R$33,508 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on BioNTech SE and its competitors. BioNTech SE's current Total Long-Term Assets is R$33,508 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNTech SE stock overvalued right now?
Based on GuruFocus' analysis, BioNTech SE (BSP:B1NT34) is currently considered Fairly Valued. The stock's GF Value™ is R$26.90, compared to a current price of R$28.53 — trading 6.1% above its estimated fair value. The current Total Long-Term Assets is R$33,508 Mil. BioNTech SE's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For BioNTech SE (BSP:B1NT34), the current Total Long-Term Assets is R$33,508 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioNTech SE (BSP:B1NT34) Overvalued in 2026?

Based on GuruFocus' analysis, BioNTech SE stock appears to be overvalued. The current stock price of R$28.53 is trading 6.1% above its estimated GF Value™ of R$26.90. GuruFocus considers BioNTech SE to be Fairly Valued.

Key valuation signals for BSP:B1NT34:

  • Total Long-Term Assets: R$33,508 Mil
  • GF Value™: R$26.90 vs. price of R$28.53 (6.1% above fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the BSP:B1NT34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioNTech SE Business Description

Address An der Goldgrube 12, Mainz, RP, DEU, D-55131
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
53GF Score

Get the complete analysis for BSP:B1NT34

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$28.53
Price
R$26.90
GF Value